Based on this evidence, we speculate that HSPA8 may be one of active sites of Roxadustat to act on hematopoietic stem cells to improve the anemia, and may affect glycolysis by regulation of glycolytic genes in hypoxia environment by up-regulating the expression of HSPA8. The gene discussed is HSPA8; the disease is anemia (phenotype).